QIAstat-Dx BCID GN Plus AMR Panel
QIAGEN GmbH · Decision date Sep 24, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-09-24 for QIAstat-Dx BCID GN Plus AMR Panel, submitted by QIAGEN GmbH of Hilden, Germany, under 510(k) number K262168. The application was received 06/26/2026 and reviewed as a traditional 510(k) by the Microbiology panel; the classification product code is PEN, under regulation number 866.3365, for Gram-Negative Bacteria And Associated Resistance Markers.
SESE in this database denotes 510(k) clearance, not premarket approval. The public record does not describe the specific components, assay targets, or changes relative to any predicate device, and no decision summary content is available in the public information. The page lists no third-party review, no combination product status, and no authorized predetermined change control plan; clinical performance data and labeling are not included here and would need to be read from the FDA decision documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Sep 24, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262168
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- QIAGEN GmbH
- Product code
- PEN
- Decision code
- SESE
- Decision date
- Sep 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Gram-Negative Bacteria And Associated Resistance Markers.
- Applicant
- QIAGEN GmbH
- Product code
- PEN
- FDA device class
- 2
FDA decision timeline
K262168 received
Application receipt date recorded by FDA.
K262168 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
QIAGEN GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hilden
Sources and methodology
- Original FDA record: K262168
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records